The FDA has approved the use of TMB (Tumor Mutation Burden) detection as a biomarker.
The FDA has approved the use of TMB (Tumor Mutation Burden) detection as a biomarker for the selection of pembrolizumab (Keytruda™) as a treatment for adults and pediatric patients with incurable or metastatic solid tumors.